Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Dec 3;2(6):442-444.
doi: 10.1016/j.jdcr.2016.05.009. eCollection 2016 Nov.

Development of bullous pemphigoid during nivolumab therapy

William Damsky  1 , Lauren Kole  1 , Mary M Tomayko  1
Affiliations
Case Reports

Development of bullous pemphigoid during nivolumab therapy

William Damsky et al. JAAD Case Rep. .
No abstract available

Keywords: BP, bullous pemphigoid; Bregs, B regulatory cells; CTLA-4, cytotoxic T-lymphocyte–associated protein 4; IRAE, immune-related adverse events; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; bullous pemphigoid; nivolumab; pembrolizumab; programmed cell death protein 1; programmed cell death protein 1 inhibitor.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Bullous pemphigoid. Representative clinical image from the right thigh.
Fig 2
Fig 2
Bullous pemphigoid. Representative clinical image from the right hand.
Fig 3
Fig 3
Bullous pemphigoid. Hematoxylin-eosin–stained section with paired immunofluorescence for complement C3 (inset).
See this image and copyright information in PMC

References

    1. Yu K.K., Crew A.B., Messingham K.A., Fairley J.A., Woodley D.T. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71:468–474. - PMC - PubMed
    1. Hwang S.J., Carlos G., Wakade D. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol. 2016;74:455–461.e1. - PubMed
    1. Hwang S.J., Carlos G., Chou S., Wakade D., Carlino M.S., Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 2016;26:413–416. - PubMed
    1. Naidoo J., Schindler K., Querfeld C. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4:383–389. - PMC - PubMed
    1. Xia Y., Jeffrey Medeiros L., Young K.H. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta. 2016;1865:58–71. - PMC - PubMed

Publication types

LinkOut - more resources